Nektar Therapeutics Q1 2026 Earnings Call Summary
Nektar Therapeutics (NKTR) reported a net loss for the first quarter of $44.9 million, or $1.82 per share, with cash and investments exceeding $1 billion as of April 2026. The company is preparing to initiate its Phase 3 program for ResPEG in atopic dermatitis by July 2026.
Tickers: $NKTR